CAV3 Gene Long QT Syndrome Type 9 Genetic Test in UAE | 2,800 AED

Executive Summary & Core Metrics

Executive Summary

Our CAV3 Genetic Test delivers definitive molecular diagnosis for Long QT Syndrome Type 9 with 99.9% diagnostic sensitivity. The service includes hospital-grade cold-chain home collection, VIP mobile phlebotomy (8 AM – 11 PM), and telephonic post-test clinical guidance. Insurance direct billing is verified via WhatsApp at +971 54 548 8731.

Accuracy: 99.9% analytical sensitivity via ISO 9001:2015 certified NGS workflow.
Logistics: Cold-chain home collection and VIP mobile phlebotomy available daily.
Clinical Guidance: Post-test tele-consultation with a cardiogenetic specialist included.

Test Overview & Methodology

The CAV3 gene NGS test comprehensively sequences the caveolin-3 gene to identify pathogenic variants responsible for Long QT syndrome type 9 – a life-threatening inherited cardiac channelopathy. This investigation enables precise risk stratification and personalized anti-arrhythmic or device therapy to prevent sudden cardiac death.

Feature	Our CAV3 NGS Test	Closest Alternative (Single‑Gene Sanger)
Precision	99.9% sensitivity (full coding region)	~98% (limited to one amplicon)
Method	Next‑Generation Sequencing (Illumina® platform)	Sanger sequencing
TAT	3–4 weeks	6–8 weeks
Clinical Report	Includes pharmacogenomic and family counselling note	Basic variant description

Physician Insight & Safety Protocols

"Every CAV3 variant must be correlated with clinical phenotype and family history; a negative test does not exclude other forms of Long QT syndrome. Genetic counselling before and after testing is essential to ensure accurate variant interpretation and appropriate clinical management."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Medication Safety Advisory

⚠️ Do not discontinue prescribed anti-arrhythmic or beta-blocker medication without consulting your attending cardiologist. Genetic results are only one part of a comprehensive cardiac evaluation. Always continue your current medications unless explicitly advised otherwise by your treating physician.

Exclusion Criteria & Emergency Red Flags

Acute myocardial infarction or unstable angina within last 30 days – delay testing until stabilised.
Persistent ventricular tachycardia or recent cardiac arrest – requires emergency treatment before sample collection.
Emergency Red Flags: syncope with convulsions, aborted sudden cardiac arrest, family history of sudden death under 40 years. Call 998 immediately.

Patient FAQ & Clinical Guidance

1. What exactly does the CAV3 gene test diagnose?

Our CAV3 gene NGS test definitively diagnoses Long QT syndrome type 9 by identifying pathogenic variants. It pinpoints specific DNA changes in the caveolin-3 gene that disrupt cardiac ion channels, causing prolonged QT intervals and dangerous arrhythmias. Combined with a clinical pedigree, it provides a precise molecular diagnosis that guides implantable cardioverter-defibrillator decisions and beta-blocker titration.

2. How should I prepare before giving the sample?

Bring a complete clinical history and a drawn pedigree chart of family members affected by Long QT syndrome. Genetic counselling before sampling is mandatory; our team arranges a complimentary pre-session to document three-generation family history. No fasting is required; a simple blood draw, one drop on an FTA card, or previously extracted DNA is accepted. Continue all medications unless your cardiologist advises otherwise.

3. How long do results take and what happens after I receive them?

Results are delivered in a fully interpreted clinical report within 3–4 weeks, followed by a scheduled tele-counselling session. The report includes variant classification by ACMG guidelines, potential pharmacogenetic implications, and actionable recommendations. A genetic counsellor and a cardiologist will jointly review the findings with you, address family screening needs, and coordinate with your primary physician to adjust the treatment plan safely.

4. Will my insurance cover this genetic test?

We verify your insurance coverage and direct billing options before sample collection. Contact our billing team via WhatsApp at +971 54 548 8731 with your insurance policy details. We work with most major UAE insurers and provide a clear cost estimate upfront, including any co-pay or deductible amounts.

UAE Regulatory & Data Privacy Adherence

This service fully adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is stored on encrypted UAE-based servers. Your privacy and data security remain our highest priority throughout the testing process.

Clinical & Logistical Metadata

Test Name	CAV3 Gene Long QT Syndrome Type 9 Genetic Test (NGS)
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks
Sample Type / Matrix	Peripheral whole blood (3–5 mL in EDTA tube), FTA card blood spot, or previously extracted DNA
Methodology Used	Next-Generation Sequencing (NGS) – Illumina® platform, full coding region coverage
ICD-10-CM Code	I45.81
LOINC Code	21636-6
DHA Facility License & Laboratory Address	DHA Facility License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE